Clinical Report: Immune and Cellular Factors Shaping HMA–Venetoclax Response in AML
Overview
The article describes a retrospective cohort of 132 patients with AML treated with hypomethylating agent–venetoclax therapy and single-cell transcriptomic profiling in a selected subset of 10 patients. Its stated objective was to investigate molecular and immune features associated with response, focusing on early treatment timepoints; the supplied material contains methods and clinical context but no study results.
Background
AML is genomically heterogeneous, and although HMA–venetoclax therapy has increased response rates, durable remissions remain uncommon and resistance frequently occurs. Resistance mechanisms described in the article include increased expression of alternative anti-apoptotic proteins, BAX mutations, and alterations involving TP53, NRAS, and FLT3. The article also notes that the tumor microenvironment and immune dysfunction may contribute to treatment failure, while the role of immune dysregulation in venetoclax resistance remains poorly characterized. HMA–venetoclax is used in lower-intensity treatment approaches, including for older or unfit patients.
Data Highlights
Study feature
Reported information
Retrospective cohort
132 patients with AML treated with HMA–venetoclax
Single-cell profiling subset
10 patients with newly diagnosed de novo AML
Sampling timepoints
Diagnosis (TP1) and after cycle one (TP2); median TP2 was Day 27 (range 24–51)
Response categories
Responders (CR/CRi), early relapse (initial response at TP2 followed by treatment failure within the first 4 cycles), and refractory disease (active disease at TP2)
Single-cell sequencing targets
Intended depth of 100,000 reads per cell for gene expression and 15,000 reads per cell for TCR
Key Findings
The study used retrospective clinical and genomic data from 132 patients receiving HMA–venetoclax and single-cell transcriptomic profiling from a selected subset of 10 patients.
Bone marrow samples for single-cell analysis were collected at diagnosis and after the first treatment cycle, at a median of Day 27.
Patients in the single-cell analysis were classified as responders, early relapse, or refractory; early relapse and refractory cases were combined as non-responders for binary comparisons.
The investigators used a custom 73-gene panel for genomic profiling and single-cell gene-expression and T-cell receptor sequencing.
The article identifies alternative anti-apoptotic protein expression, BAX mutations, and TP53, NRAS, and FLT3 alterations among molecular processes associated with HMA–venetoclax resistance.
The supplied article material states that immune dysregulation’s role in venetoclax resistance is poorly characterized; it does not provide the study’s outcome or immune-profile results.
Clinical Implications
The supplied material describes the study design and rationale but does not report results that support specific clinical decisions or treatment recommendations. It therefore does not establish how the investigated immune or cellular features relate to response in this cohort.
Conclusion
This study was designed to examine early molecular and immune features associated with HMA–venetoclax response in AML using bulk genomic profiling and single-cell transcriptomics. The provided text does not include the findings needed to characterize those associations.
